CagriSema vs. Semaglutide vs. Tirzepatide: Parsing the Latest Head-to-Head Weight-Loss Data

CagriSema — a once-weekly co-formulation of the amylin analog cagrilintide and the GLP-1 agonist semaglutide — has entered late-phase trials and is already drawing comparisons with today’s heavy-hitters, semaglutide and tirzepatide. Below, we break down what the newest REDEFINE and SURMOUNT datasets tell us about efficacy, safety, and who might benefit most.

Last updated August 2026

What Is CagriSema and How Does It Differ From Current GLP-1 Therapies?

CagriSema combines semaglutide (a glucagon-like peptide-1 receptor agonist) with cagrilintide, an investigational analog of amylin — a satiety hormone co-secreted with insulin. By activating both GLP-1 and amylin pathways, the drug aims to amplify appetite suppression, slow gastric emptying, and improve glucose control beyond what either hormone can achieve alone. (nejm.org)

Semaglutide (Wegovy) and tirzepatide (Zepbound) are currently FDA-approved for chronic weight management. Tirzepatide is a single peptide that stimulates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, whereas CagriSema delivers two distinct molecules in one pen.

How Much Weight Loss Has CagriSema Shown in Clinical Trials?

The pivotal REDEFINE program includes multiple phase 3 trials. In REDEFINE 1, adults without diabetes lost an average of 20.4 % of baseline body weight at 68 weeks on CagriSema 2.4 mg/2.4 mg. (acc.org) A companion study in people with type 2 diabetes (REDEFINE 2) reported similar relative reductions. (nejm.org)

Responder analyses are equally impressive: 92 % of CagriSema participants achieved at least 5 % weight loss, and 54 % crossed the 20 % threshold. (pmc.ncbi.nlm.nih.gov)

How Does CagriSema’s Efficacy Compare With Semaglutide Alone?

Within REDEFINE 1, CagriSema outperformed semaglutide 2.4 mg by 5.5 percentage points. At week 68, the least-squares mean difference favored CagriSema −5.5 % (95 % CI −6.3 to −4.7; p<0.001). (acc.org) Even when accounting for treatment discontinuation and rescue medications, the superiority persisted.

For context, semaglutide’s STEP program documented 14.9 % loss at 68 weeks, establishing the drug as a benchmark in 2021. CagriSema appears to raise that bar, though the combination is not yet FDA-approved.

How Does CagriSema Stack Up Against Tirzepatide?

No direct head-to-head trial exists, but cross-trial comparisons suggest near-parity:

• CagriSema: 20.4 % loss at 68 weeks (REDEFINE 1) (acc.org)
• Tirzepatide: 20.9 % loss at 72 weeks (SURMOUNT-5) (investor.lilly.com)

The overlapping confidence intervals mean neither agent clearly “wins” on weight loss. However, tirzepatide currently enjoys FDA approval and commercial availability, whereas CagriSema remains investigational.

Although GI symptoms are most frequent with CagriSema, the discontinuation rate is similar to semaglutide and only slightly higher than tirzepatide. (pubtexto.com) Long-term tolerability remains to be confirmed in broader populations.

What Do Safety and Side-Effect Profiles Look Like?

All three agents share class-typical GI effects — nausea, vomiting, and diarrhea — that peak during dose escalation. According to FDA labeling, nausea occurs in up to 44 % of semaglutide users and 21 % of tirzepatide users at maintenance dose. (accessdata.fda.gov) In REDEFINE 1, GI events of any severity affected 79.6 % of CagriSema participants. (novonordisk.com)

Other considerations:

• Pancreatitis and gallbladder disease: Warnings are identical across products and stem from the GLP-1 class effect.
• Medullary thyroid carcinoma (MTC): Contraindication applies to all three because of rodent data.
• Hypoglycemia: Low risk unless combined with insulin or sulfonylureas.
• Cardiovascular outcomes: Semaglutide’s SELECT trial showed a 20 % reduction in major CV events; similar outcome data for tirzepatide and CagriSema are pending.

Which Patients Might Benefit Most From CagriSema?

What Higher-Dose and Future Trials Are Planned?

Novo Nordisk plans to initiate a phase 3 program evaluating a higher-dose CagriSema pen (exact dosing undisclosed) in the second half of 2026, with top-line results anticipated in 2027 (REDEFINE 11). (novonordisk.com) Early phase-2 modeling suggests an additional 2–3 percentage-point weight-loss advantage at the higher dose, though tolerability will be closely monitored.

Cardiovascular outcome trials are also in the works, aiming to replicate the benefit seen with semaglutide’s SELECT study. Until those results materialize, payers may hesitate to reimburse CagriSema broadly.

How Can You Talk to Your Healthcare Provider About These Options?

Prepare a medication history, weight-loss goals, and concerns about side effects before your visit. This question checklist can streamline the discussion. If access is a barrier, learn how online prescription visits work and compare prices using trusted tools.

When to Contact Your Healthcare Provider

• Persistent nausea or vomiting that prevents you from keeping fluids down
• Severe abdominal pain, which could signal pancreatitis or gallbladder disease
• Signs of thyroid tumor, such as a neck lump or hoarseness
• Symptoms of allergic reaction: rash, itching, swelling of the face or throat
• Persistent low blood sugar (if you also use insulin or sulfonylureas)
• Mental health changes, including new or worsening depression